Ke‐Da Yu

机构：Fudan University Shanghai Cancer Center, Shanghai Cancer Institute · ORCID：0000-0002-2883-1282

发表论文 308 篇 · 总被引 11284 次 · h-index 51

代表论文

• Breast cancer: pathogenesis and treatments (2025 · Signal Transduction and Targeted Therapy · 被引 907)
• Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy (2025 · The Lancet · 被引 36)
• Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase II trial (2025 · Annals of Oncology · 被引 32)
• Circulating Tumor Microenvironment in Metastasis (2025 · Cancer Research · 被引 28)
• RNA modifications in the tumor microenvironment: insights into the cancer-immunity cycle and beyond (2025 · Experimental Hematology and Oncology · 被引 25)
• A prospective, phase II, neoadjuvant study based on chemotherapy sensitivity in HR+/HER2‐ breast cancer‐FINEST study (2025 · 癌症：英文版 · 被引 11)